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Abstract
Background: Lipid profiles appear to be altered in rheumatoid arthritis (RA) patients because of disease activity and
inflammation. Cholesterol efflux capacity (CEC), which is the ability of high-density lipoprotein cholesterol to accept
cholesterol from macrophages, has been linked not only to cardiovascular events in the general population but
also to being impaired in patients with RA. The aim of this study was to establish whether CEC is related to
subclinical carotid atherosclerosis in patients with RA.
Methods: We conducted a cross-sectional study that encompassed 401 individuals, including 178 patients with RA
and 223 sex-matched control subjects. CEC, using an in vitro assay, lipoprotein serum concentrations, and standard
lipid profile, was assessed in patients and control subjects. Carotid intima-media thickness (CIMT) and carotid
plaques were assessed in patients with RA. A multivariable analysis was performed to evaluate the relationship of
CEC with RA-related data, lipid profile, and subclinical carotid atherosclerosis.
Results: Mean (SD) CEC was not significantly different between patients with RA (18.9 ± 9.0%) and control subjects
(16.9 ± 10.4%) (p = 0.11). Patients with RA with low (β coefficient −5.2 [−10.0 to 0.3]%, p = 0.039) and moderate
disease activity (β coefficient −4.6 [−8.5 to 0.7]%, p = 0.020) were associated with lower levels of CEC than patients
in remission. Although no association with CIMT was found, higher CEC was independently associated with a lower
risk for the presence of carotid plaque in patients with RA (odds ratio 0.94 [95% CI 0.89–0.98], p = 0.015).
Conclusions: CEC is independently associated with carotid plaque in patients with RA.
Keywords: Rheumatoid arthritis, Cholesterol efflux capacity, Carotid intima-media thickness, Cardiovascular disease
Background
Patients with rheumatoid arthritis (RA) have higher rates
of morbidity and mortality than the general population,
which has been widely attributed to these patients’ in-
creased risk of cardiovascular disease [1]. Besides a genetic
component and the influence of traditional cardiovascular
risk factors [2], chronic inflammation seems to play a
pivotal role in the process of accelerated atherogenesis ob-
served in RA [3]. Several studies support the notion that
RA leads to a more atherogenic lipid profile, which corre-
lates with disease activity and improves after treatment
with antirheumatic medications [4]. Paradoxically, these
lipid changes generally account for a decrease in total
cholesterol and low-density lipoprotein (LDL) cholesterol
[5, 6]. The exact mechanism that leads to this paradoxical
lipid profile in patients with RA and the implications
regarding cardiovascular risk are still being studied.
High-density lipoprotein (HDL) cholesterol efflux cap-
acity (CEC), which is the ability of HDL to accept
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cholesterol from macrophages, is a key step in reverse
cholesterol transport. It has been shown to be inversely
associated, independent of HDL cholesterol levels, with
both carotid intima-media thickness (CIMT) and the
likelihood of angiographic coronary artery disease [7], as
well as with a higher incidence of cardiovascular events,
in population-based cohorts [8]. It is known that CEC is
impaired in patients with RA and that this correlates
with systemic inflammation and HDL’s antioxidant cap-
acity [9, 10]. However, the implications of this impaired
CEC in the development of subclinical atherosclerosis in
patients with RA have not yet been studied.
The aim of this study was to analyze whether CEC is
related to subclinical atherosclerosis as determined by
the presence of carotid plaque or increased levels of
CIMT in patients with RA. Secondarily, we aimed to de-
scribe the disease-contributing factors that are related to
CEC as an expression of the abnormalities in the lipid
profile associated with the disease. If CEC is related to
subclinical atherosclerosis in patients with RA, this
effect would shed light on the complex connections be-




This was a cross-sectional study that included 401 indi-
viduals, 223 patients with RA, and 178 sex-matched
control subjects. All patients with RA were 18 years old
or older and fulfilled the 2010 American College of
Rheumatology/European League Against Rheumatism
diagnostic criteria for RA [11]. They had been diagnosed
by rheumatologists and were periodically followed at
rheumatology outpatient clinics. For the purpose of in-
clusion in the present study, RA disease duration was re-
quired to be ≥1 year. Although anti-tumor necrosis
factor-α (anti-TNF-α) treatment has been associated
with changes in lipid profiles [12], patients with RA
undergoing TNF-α antagonist or other biologic therapies
were not excluded from the present study. The control
group consisted of patients recruited from the Spanish
Camargo Cohort Study [13, 14]. This cohort was set up
between February 2006 and February 2011, and individ-
uals included in this cohort have been followed ever
since. The original aim of using this cohort was to
evaluate the prevalence and incidence of metabolic bone
diseases and mineral metabolism disorders. Control sub-
jects included in the present study were sex-matched
subjects without any known condition or drug treatment
history that could influence lipids and who were not tak-
ing any lipid-lowering medications other than statins.
None of the control subjects were receiving glucocorti-
coids. However, because prednisone is often used in the
management of RA, patients taking prednisone or an
equivalent dose ≤10 mg/day were not excluded. As
previously mentioned, both patients and control subjects
receiving statin treatment were allowed to participate in
the study. Patients and control subjects were excluded if
they had a history of myocardial infarction, angina,
stroke, a glomerular filtration rate <60 ml/minute/
1.73 m2, a history of cancer or any other chronic disease,
or evidence of active infection. The study protocol was
approved by the institutional review committees at Hos-
pital Universitario de Canarias and Hospital Universi-
tario Marqués de Valdecilla (both in Spain), and all
subjects provided written informed consent.
Data collection
The subjects, both control subjects and patients, com-
pleted a cardiovascular risk factor and medication use
questionnaire and underwent a physical examination.
Weight, height, body mass index, waist-to-hip ratio, and
systolic and diastolic blood pressure (measured with the
participant in a supine position) were assessed under
standardized conditions. Information regarding smoking
status (current smoker versus nonsmoker), diabetes, and
hypertension was obtained from the questionnaire. Med-
ical records were reviewed to ascertain specific diagnoses
and medications. Dyslipidemia was defined as present if
one of the following was measured: total cholesterol
>200 mg/dl, triglycerides >150 mg/dl, HDL cholesterol
<40 in men or <50 mg/dl in women, or LDL cholesterol
>130 mg/dl. Disease activity in patients with RA was
measured using the Disease Activity Score in 28 joints
(DAS28) [15], the Clinical Disease Activity Index (CDAI)
[16], and the Simplified Disease Activity Index [17].
Patients with RA were defined as being in clinical remis-
sion (DAS28 < 2.6) or having low (DAS28 in the range of
2.6–3.2), moderate (DAS28 > 3.2–5.1), or high (DAS28 >
5.1) disease activity as previously described [18].
Lipids and cholesterol efflux assessments
Fasting serum samples were collected and frozen at
−80 °C until analysis of circulating lipids. Cholesterol,
triglycerides, and HDL cholesterol were measured using
an enzymatic colorimetric assay (Roche Diagnostics, In-
dianapolis, IN, USA). Cholesterol levels ranged from
0.08 to 20.7 mmol/L (intra-assay coefficient of variation
0.3%); triglyceride levels ranged from 4 to 1.000 mg/dl
(intra-assay coefficient of variation 1.8%); and HDL chol-
esterol levels ranged from 3 to 120 mg/dl (intra-assay
variation coefficient 0.9%). LDL cholesterol was calcu-
lated using the Friedewald formula [19]. A standard
technique was used to measure the erythrocyte sedimen-
tation rate (ESR) and high-sensitivity C-reactive protein
(CRP) level.
Macrophage-specific CEC was measured using boron-
dipyrromethene (BODIPY) cholesterol as previously
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described [8]. Briefly, J774 macrophages were seeded
into a 96-well plate at 7 × 104 cells per well. The follow-
ing day, the cells were incubated for 1 h with BODIPY-
tagged cholesterol (25 μM; Avanti Polar Lipids, Alabas-
ter, AL, USA), 0.2% bovine serum albumin (BSA), and
2 μg/ml acetyl-coenzyme A acetyltransferase (ACAT)
inhibitor (Sandoz; Sigma-Aldrich, St. Louis, MO, USA)
in RPMI 1640 medium plus 1% FBS. Following a wash-
ing step with minimal essential medium (MEM)-HEPES,
cells were incubated overnight in serum-free RPMI 1640
medium containing 0.3 mM cyclic adenosine monopho-
sphate (cAMP), 0.2% BSA, and 2 μg/ml ACAT inhibitor.
Apolipoprotein B-depleted study subject plasma was pre-
pared using polyethylene glycol precipitation. After a wash-
ing step with MEM-HEPES, the BODIPY cholesterol-
labeled cells were incubated with 2.8% apolipoprotein B-
depleted plasma in MEM-HEPES buffer, 0.15 mM cAMP,
and 2 μg/ml ACAT inhibitor for 4 h at 37 °C. The resulting
quantity of BODIPY cholesterol in the media was measured
directly using a spectrofluorometric plate reader (Tecan
Trading AG, Männedorf, Switzerland) with an excitation
wavelength of 485 nm and emission detection at 530 nm.
The CEC was calculated as the amount of BODIPY choles-
terol efflux expressed as a fraction of the initial cell content
of BODIPY cholesterol. Each assay was performed in tripli-
cate, and when the percentage of variation of every sample
was >7%, the sample was reassessed.
Carotid ultrasound assessment
A carotid ultrasound examination was used to assess
CIMT in the common carotid arterial wall and to detect
focal plaques in the extracranial carotid tree in patients
with RA. A commercially available scanner, the MyLab
70 (Esaote, Genoa, Italy), equipped with a 7- to 12-MHz
linear transducer and using an automated software-
guided radiofrequency technique called quality intima-
media thickness in real time was used for this purpose.
As previously reported [20], on the basis of the Mann-
heim consensus, plaque criteria in the accessible extra-
cranial carotid tree (common carotid artery, bulb, and
internal carotid artery) were defined as follows: a focal
protrusion in the lumen measuring CIMT ≥1.5 mm, a
protrusion ≥50% greater than the surrounding CIMT, or
arterial lumen encroaching >0.5 mm [21].
Statistical analysis
In terms of study power, we found a correlation between
HDL cholesterol and CIMT (r = −0.161, p = 0.034). We
expected to find a similar relation between CEC and
CIMT. To achieve power of 80% to detect differences in
the contrast of the null hypothesis, based on assuming a
significance bilateral level of 0.05 and by means of
analysis of variance in the context of a multiple linear
regression model with an expected final determination
coefficient of 0.05, it was necessary to include 152 sub-
jects in the study. Demographic and clinical characteris-
tics shown in Table 1 were compared between patients
with RA and control subjects using χ2 tests for categor-
ical variables or Student’s t test for continuous variables
(data expressed as mean ± SD). For noncontinuous vari-
ables, either the Mann-Whitney U test was performed
or a logarithmic transformation was performed, and data
are expressed as median and IQR. Univariate linear and
logistic regression analyses were performed to establish
the relationship of demographics, traditional cardiovas-
cular risk factors, lipid profiles, RA-related data, and
CEC with both CIMT and the presence of carotid
plaque. The relation of CEC with carotid assessments
was determined through multivariate linear and logistic
regression analysis, adjusting for confounding factors.
For the purpose of this study, confounding variables
were those with a statistical p value <0.20 in the associ-
ation analysis vis-à-vis both carotid assessment and
CEC. For all analyses, we used a 5% two-sided signifi-
cance level, and all analyses were performed using IBM
SPSS Statistics version 21 software (IBM, Armonk, NY,
USA) and Stata version 13/SE software (StataCorp, Col-
lege Station, TX, USA). A p value <0.05 was considered
statistically significant.
Results
Demographic, laboratory, and disease-related data
A total of 401 sex-matched participants, 178 patients
with RA, and 223 control subjects were included in this
study. Demographic and disease-related characteristics
of the participants are shown in Table 1. There were no
differences between patients and control subjects with
regard to body mass index. However, abdominal circum-
ference and the presence of hypertension, dyslipidemia,
or diabetes were more common in patients with RA.
Similarly, statin intake was more frequently observed in
patients with RA than in control subjects (34% versus
10%, p = 0.000). Patients with RA had moderately active
disease, as shown by the mean DAS28 (3.74 ± 1.19).
More than one-third (35%) were taking prednisone (me-
dian dose of the 62 patients on prednisone was 5 [IQR
3–6] mg/day at the time of the study). As expected, ESR
values were statistically significantly higher in patients
than in control subjects. One hundred nineteen (67%)
patients had positive test results for rheumatoid factor,
153 (86%) were taking disease-modifying antirheumatic
drugs, and 23 (13%) were receiving anti-TNF-α therapy.
The mean CEC of HDL was not significantly different
between patients with RA (18.9 ± 9.0%) and control sub-
jects (16.9 ± 10.4%) (p = 0.11). This difference remained
nonsignificant after adjusting for HDL cholesterol levels,
age, sex, and statin use (data not shown).
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Relationship of CEC with demographic, traditional
cardiovascular risk factors, and disease-related data in
patients and control subjects
Demographic variables were not associated with CEC,
except for a correlation with male sex that was found
only in patients with RA and not in control subjects.
Systolic blood pressure was inversely correlated with
CEC in control subjects (β coefficient −0.1 [−0.2 to
0.0]%, p = 0.025). In patients with RA, a similar trend
was found, although a statistically significant difference
was not reached. Neither the traditional cardiovascular
risk factors nor the cardiovascular comorbidity-related
data were associated with CEC. Similarly, the lipid pro-
file did not show any relationship with CEC in patients
or control subjects (Table 2).
Disease activity, when considered continuous, was not
associated with lower levels of CEC (β coefficient −1.1
[−2.3 to 0.2]%, p = 0.086). Nevertheless, when patients
were stratified according to the degree of disease activity,
some differences were seen. With respect to this, the pa-
tient subgroup that exhibited low (β coefficient −5.2
[−10.0 to 0.3]%, p = 0.039) and moderate (β coefficient
−4.6 [−8.5 to 0.7]%, p = 0.020) disease activity was asso-
ciated with statistically significant lower levels of CEC
than those in clinical remission. Although no association
was found when patients with RA with high disease ac-
tivity were compared with those in remission (β







Age, years 59 ± 9 55 ± 11 0.000
Female sex, n (%) 155 (70) 140 (79) 0.063
Body mass index, kg/m2 28 ± 5 28 ± 5 0.74
Abdominal circumference,
cm
93 ± 14 97 ± 13 0.006
Systolic blood pressure,
mmHg
133 ± 15 137 ± 19 0.018
Diastolic blood pressure,
mmHg
82 ± 10 83 ± 12 0.36
Cardiovascular comorbidity
Smoking, n (%) 45 (20) 29 (16) 0.29
Diabetes, n (%) 10 (4) 27 (15) 0.000
Hypertension, n (%) 64 (29) 62 (35) 0.22
Dyslipidemia, n (%) 41 (18) 71 (40) 0.000
Antihypertensive
treatment, n (%)
38 (17) 63 (35) 0.000
Statins, n (%) 22 (10) 60 (34) 0.000
Hormone replacement
therapy, n (%)
7 (3) 0 (0) 0.018
Laboratory examinations, including lipid profile
ESR, mm/h 10 ± 8 35 ± 22 0.000
CRP, mg/dl 1.0 (1.0–3.0) 3.3 (1.6–6.1) 0.34
Cholesterol, mg/dl 218 ± 39 206 ± 37 0.001
Triglycerides, mg/dl 105 ± 52 151 ± 92 0.000
HDL cholesterol, mg/dl 63 ± 17 56 ± 16 0.000
LDL cholesterol, mg/dl 134 ± 36 120 ± 33 0.000
Lipoprotein A, mg/dl 16 (9–35) 33 (10–121) 0.000
Apolipoprotein A, mg/dl 191 ± 35 170 ± 28 0.000
Apolipoprotein B, mg/dl 102 ± 24 109 ± 59 0.13
ApoB/ApoA ratio 0.55 ± 0.16 0.65 ± 0.29 0.000
Atherogenic index 3.72 ± 1.14 4.02 ± 1.51 0.036
Cholesterol efflux
capacity, %
16.9 ± 10.4 18.9 ± 9.0 0.11
Rheumatoid arthritis-related data
Disease duration, years 7 (4–15)
Age at onset, years 45 ± 13
DAS28 3.74 ± 1.19
Remission, n (%) 38 (21)
Low activity, n (%) 29 (16)
Moderate activity, n (%) 84 (47)
High activity, n (%) 27 (15)
DAS28-CRP 2.94 ± 0.99
SDAI 14 (8–21)
CDAI 82 (40–112)
Rheumatoid factor, n (%) 119 (67)
Table 1 Characteristics of patients with rheumatoid arthritis and
control subjects (Continued)
ACPA, n (%) 98 (55)
Prednisone intake, n (%) 62 (35)
Prednisone dose, mg/day 5 (3–6)
NSAIDs, n (%) 78 (44)
DMARDs, n (%) 153 (86)
Methotrexate, n (%) 135 (76)
Leflunomide, n (%) 19 (11)
Biologic therapy, n (%) 41 (23)
Anti-TNF-α therapy, n (%) 23 (13)
Tocilizumab, n (%) 11 (6)
Rituximab, n (%) 5 (3)
Abatacept, n (%) 2 (1)
Carotid assessments
CIMT, mm 0.671 ± 0.143
Carotid plaque, n (%) 66 (37)
Data represent mean (SD) or median (IQR) when data were not
normally distributed
Abbreviations: CRP C-reactive protein, LDL Low-density lipoprotein, NSAID Non-
steroidal anti-inflammatory drug; DMARD Disease-modifying antirheumatic
drug, ESR Erythrocyte sedimentation rate, DAS28 Disease Activity Score in 28
joints, HDL High-density lipoprotein, SDAI Simplified Disease Activity Index,
CDAI Clinical Disease Activity Index, TNF-α Tumor necrosis factor-α, ACPA
Anticitrullinated protein antibody, CIMT Carotid intima-media thickness. Signifi-
cant 'p' values are higlighted in italics
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Table 2 Univariate relationship of traditional cardiovascular risk factors and rheumatoid arthritis-related data with high-density
lipoprotein cholesterol efflux capacity in control subjects and patients with rheumatoid arthritis
Control subjects Patients with RA
Percent efflux β coefficient (95% CI) p Value Percent efflux β coefficient (95% CI) p Value
Age, years −0.9 (−0.4 to 0.2) 0.50 −0.2 (−0.2 to 0.1) 0.78
Male sex −0.9 (−4.6 to 2.8) 0.62 −6.1 (−9.4 to 2.8) 0.000
Body mass index −0.2 (−0.6 to 0.1) 0.20 0.2 (−0.1 to 0.5) 0.21
Abdominal circumference −0.1 (−0.2 to 0.0) 0.058 0.0 (−0.1 to 0.2) 0.42
Systolic blood pressure −0.1 (−0.2 to 0.0) 0.025 0.1 (−0.0 to 0.2) 0.11
Diastolic blood pressure −0.0 (-0.1 to 0.0) 0.29 0.01 (−0.0 to 0.2) 0.15
Cardiovascular comorbidities
Smoking 1.8 (−2.4 to 6.0) 0.40 −0.3 (−4.5 to 3.9) 0.89
Diabetes 1.2 (−5.9 to 8.3) 0.74 2.9 (−1.3 to 7.2) 0.17
Hypertension −2.4 (−6.0 to 1.1) 0.17 0.1 (−3.0 to 3.2) 0.95
Dyslipidemia −1.1 (−5.2 to 3.1) 0.61 −0.3 (−3.4 to 2.8) 0.85
Antihypertensive treatment 0.7 (−3.6 to 5.0) 0.75 0.4 (−2.7 to 3.5) 0.80
Statins −2.1 (−7.4 to 3.2) 0.44 0.6 (−2.6 to 3.8) 0.70
Laboratory examinations, including lipid profile
ESR −0.2 (−0.1 to 0.1) 0.23 −0.1 (−0.1 to 0.0) 0.12
CRP −0.3 (−0.6 to 0.0) 0.092 −0.0 (−0.1 to 0.1) 0.83
Cholesterol 0.0 (−0.0 to 0.1) 0.11 0.00 (−0.0 to 0.00) 0.69
Triglycerides −0.0 (−0.1 to 0.0) 0.19 0.0 (−0.0 to 0.0) 0.30
HDL cholesterol 0.1 (−0.0 to 0.2) 0.092 0.0 (−0.1 to 0.1) 0.48
LDL cholesterol 0.0 (−0.0 to 0.1) 0.32 −0.0 (−0.1 to 0.0) 0.62
Lipoprotein A 0.1 (−0.0 to 0.1) 0.059 −0.0 (−0.0 to 0.0) 0.35
Apolipoprotein A 0.0 (−0.0 to 0.1) 0.089 −0.0 (−0.1 to 0.0) 0.84
Apolipoprotein B 0.0 (−0.1 to 0.1) 0.77 0.00 (−0.0 to 0.0) 0.99
ApoB/ApoA ratio −5.8 (−16.8 to 5.4) 0.31 0.8 (−4.1 to 5.7) 0.76
Atherogenic index 0.7 (−2.4 to 1.0) 0.41 0.0 (−1 to 1) 0.99
Rheumatoid arthritis-related data
Disease duration 0.1 (−0.0 to 0.3) 0.12
DAS28 −1.1 (−2.3 to 0.2) 0.086
Remission –
Low disease activity −5.2 (−10.0 to 0.3) 0.039
Moderate disease activity −4.6 (−8.5 to 0.7) 0.020
High disease activity −3.2 (−8.1 to 1.7) 0.19
Moderate and high disease activity −4.2 (−7.9 to 0.6) 0.024
DAS28-CRP −1.1 (−2.7 to 0.4) 0.14
SDAI −0.0 (−0.1 to 0.1) 0.54
CDAI −0.0 (−0.0 to 0.0) 0.31
Rheumatoid factor −0.4 (−3.8 to 2.9) 0.81
ACPA 0.4 (−2.7 to 3.6) 0.78
Prednisone intake −0.3 (−3.4 to 2.9) 0.88
Prednisone dose −0.3 (−3.4 to 2.9) 0.88
NSAIDs 4.6 (1.5 to 7.6) 0.004
DMARDs −0.2 (−4.6 to 4.2) 0.93
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coefficient −3.2 [−8.1 to 1.7]%, p = 0.19), this association
was maintained when moderate and high disease activity
groups were considered as a single group (β coefficient
−4.2 [−7.9 to 0.6]%, p = 0.024).
Neither rheumatoid factor- nor anticitrullinated pro-
tein antibody (ACPA)-positive status was associated with
CEC. Apart from those patients who underwent toci-
lizumab treatment (11 patients), in whom the use of this
anti-interleukin-6 biologic agent led to higher CEC levels
(β coefficient 8.0 [2.3–13.7]%, p = 0.007), as well as a cor-
relation linking nonsteroidal anti-inflammatory drug
(NSAID) intake and a higher CEC index (β coefficient
4.6 [1.5–7.6]%, p = 0.004), no association between RA
therapy and CEC was found (Table 2).
Relationship of RA patient characteristics with CIMT and
carotid plaques
Age, male sex, waist circumference, and traditional
cardiovascular risk factors (hypertension, diabetes, and
dyslipidemia), except for smoking, positively correlated
with either the presence of carotid plaque or CIMT.
With respect to laboratory data, lipoprotein A (OR 1.00
[95% CI 1.00–1.01], p = 0.043) was associated with the
presence of carotid plaque. Whereas triglycerides (p =
0.034) and atherogenic index (p = 0.023) correlated with
higher levels of CIMT, HDL cholesterol showed a nega-
tive association with CIMT (β coefficient −0.01 [−0.03 to
0.00], p = 0.034). Levels of ESR were positively associated
with both carotid plaque and CIMT.
Regarding RA-related data, disease activity as assessed
by DAS28 (OR 1.36 [95% CI 1.05–1.77], p = 0.022) or
CDAI (OR 1.01 [95% CI 1.00–1.01], p = 0.055) was associ-
ated with a higher risk of carotid plaque involvement.
Rheumatoid factor was negatively and marginally related
to a lower level of CIMT, though no association of carotid
plaque or CIMT with ACPA status was found. NSAID in-
take was negatively associated with both carotid plaque
(OR 0.40 [95% CI 0.21–0.76], p = 0.005) and CIMT (β co-
efficient −0.6 [−1.0 to 0.2], p = 0.005) (Table 3). However,
no association between prednisone intake or prednisone
dose and carotid plaque or CIMT was found (Table 3).
CEC’s association with carotid subclinical atherosclerosis
in patients with RA
Higher CEC was associated with a protective effect
against the presence of carotid plaque in patients with
RA. This association (OR 0.94 [95% CI 0.89–0.98], p =
0.015) was maintained even after multivariate analysis
(adjusted for age, sex, systolic blood pressure, diabetes,
ESR, disease duration, DAS28, and tocilizumab use). In
contrast, CEC was not found to be associated with
CIMT in patients with RA (Table 4).
Discussion
In the present study, we show, for the first time to our
knowledge, that CEC is independently associated with
carotid plaque in patients with RA. Additionally, CEC
was shown to be inversely proportional to disease activ-
ity, with CEC being lower in patients with low or moder-
ate activity than in patients in remission.
In our study, we did not observe a difference in CEC be-
tween patients and control subjects, a finding that is in
agreement with previous reports. In fact, using an assay
similar to that of our own study, Charles-Schoeman et al.
found no significant difference between 40 patients with
RA and 40 age- and sex-matched healthy control subjects
[9]. Ronda et al. [10] studied CEC through 4 different and
specifically CEC pathways in 30 patients with RA and 30
healthy control subjects. They did not discover any
significant differences in scavenger receptor class B
member 1 (SR-BI)-mediated efflux, ATP-binding cas-
sette A1 (ABCA1)-mediated efflux, and aqueous diffu-
sion (AD) CEC pathways. Only ATP-binding cassette
G1 (ABCG1)-mediated efflux was found to be im-
paired when patients with RA were compared with
healthy control subjects.
Regarding the relationship of disease activity with
CEC, our findings are also in agreement with other
Table 2 Univariate relationship of traditional cardiovascular risk factors and rheumatoid arthritis-related data with high-density
lipoprotein cholesterol efflux capacity in control subjects and patients with rheumatoid arthritis (Continued)
Methotrexate 0.5 (−2.9 to 4.0) 0.77
Leflunomide −1.3 (−5.9 to 3.3) 0.58
Biologic therapy 3.57 (−0.0 to 7.2) 0.052
Anti-TNF-α therapy 0.7 (−4.0 to 5.5) 0.76
Tocilizumab 8.0 (2.3 to 13.7) 0.007
Rituximab 1.3 (−9.1 to 11.7) 0.81
Abatacept −1.4 (−14.1 to 11.4) 0.83
DAS28 relation with cholesterol efflux capability was studied using remission category as the reference category
Abbreviations: CRP C-reactive protein, LDL Low-density lipoprotein, NSAID Nonsteroidal anti-inflammatory drug; DMARD Disease-modifying antirheumatic drug, ESR
Erythrocyte sedimentation rate, DAS28 Disease Activity Score in 28 joints, HDL High-density lipoprotein, SDAI Simplified Disease Activity Index, CDAI Clinical Disease
Activity Index, TNF-α Tumor necrosis factor-α, ACPA Anticitrullinated protein antibody, CIMT Carotid intima-media thickness, ApoA Apolipoprotein A, ApoB Apolipo-
protein B. Significant 'p' values are higlighted in italics
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Table 3 Univariate relationship of characteristics of patients with rheumatoid arthritis with carotid intima-media thickness and
carotid plaques
Carotid plaque CIMT (×10 mm)
Patients with RA (n = 178) OR (95% CI) p Value β Coefficient (95% CI) p Value
Age 1.15 (1.10–1.20) 0.000 0.08 (0.01–0.01) 0.000
Male sex 3.00 (1.44–6.26) 0.003 1.1 (0.6–1.6) 0.000
Body mass index 1.00 (0.95–1.06) 0.92 0.03 (0.02–0.07) 0.23
Abdominal circumference 1.01 (0.99–1.04) 0.31 0.02 (0.00–0.03) 0.021
Systolic blood pressure 1.04 (1.02–1.06) 0.000 0.04 (0.03–0.05) 0.000
Diastolic blood pressure 1.02 (0.997–1.05) 0.078 0.02 (0.01–0.04) 0.009
Cardiovascular comorbidity
Smoking 1.04 (0.46–2.37) 0.92 −0.1 (0.7 to 0.4) 0.63
Diabetes 3.54 (1.51–8.30) 0.004 1.0 (0.04 to 1.6) 0.001
Hypertension 2.57 (1.36–4.87) 0.004 0.6 (0.2 to 1.1) 0.005
Dyslipidemia 3.61 (1.91–6.84) 0.000 0.4 (−0.01 to 0.8) 0.082
Antihypertensive treatment 2.73 (1.44–5.18) 0.002 0.7 (0.2 to 1.1) 0.002
Statins 3.93 (2.04–7.58) 0.000 0.5 (0.0 to 0.9) 0.036
Laboratory including lipid profile
ESR 1.02 (1.01–1.04) 0.003 0.01 (0.00 to 0.02) 0.041
CRP 0.45 (0.96–1.02) 0.45 0.00 (−0.01 to 0.01) 0.947
Cholesterol 1.00 (0.99–1.01) 0.83 0.00 (0.00 to 0.01) 0.16
Triglycerides 1.00 (0.99–1.01) 0.13 0.00 (0.00 to 0.00) 0.034
HDL cholesterol 0.99 (0.98–1.01) 0.51 −0.01 (−0.03 to 0.00) 0.034
LDL cholesterol 0.99 (0.99–1.01) 0.77 0.00 (0.00 to 0.01) 0.14
Lipoprotein A 1.00 (1.00–1.01) 0.043 0.00 (0.00 to 0.00) 0.76
Apolipoprotein A 1.01 (0.99–1.02) 0.37 0.00 (−0.01 to 0.01) 0.80
Apolipoprotein B 0.99 (0.99–1.01) 0.73 0.00 (0.00 to 0.00) 0.48
ApoB/ApoA ratio 0.70 (0.21–2.33) 0.56 0.4 (0.4 to 1.1) 0.36
Atherogenic index 1.06 (0.87–1.29) 0.57 0.2 (0.0 to 0.3) 0.029
Rheumatoid arthritis-related data
Disease duration 1.02 (0.99–1.06) 0.17 0.01 (−0.01 to 0.03) 0.41
DAS28 1.36 (1.05–1.77) 0.022 0.12 (−0.06 to 0.30) 0.18
DAS28-CRP 1.19 (0.88–1.63) 0.26 0.08 (−0.14 to 0.29) 0.47
SDAI 0.99 (0.98–1.02) 0.85 0.00 (−0.01 to 0.01) 0.76
CDAI 1.01 (1.00–1.01) 0.055 0.00 (0.00 to 0.01) 0.16
Rheumatoid factor 0.87 (0.45–1.71) 0.69 −0.5 (−1.0 to 0.0) 0.043
ACPA 0.87 (0.46–1.63) 0.66 −0.3 (−0.8 to 0.1) 0.14
Prednisone intake 1.11 (0.59–2.10) 0.74 0.0 (−0.4 to 0.5) 0.90
Prednisone doses 0.99 (0.89–1.09) 0.81 −0.04 (−0.1 to 0.2) 0.20
NSAIDs 0.40 (0.21–0.76) 0.005 −0.6 (−1.0 to 0.2) 0.005
DMARDs 2.04 (0.77–5.41) 0.15 0.3 (−0.4 to 0.9) 0.43
Methotrexate 0.77 (0.38–1.54) 0.46 −0.3 (−0.8 to 0.2) 0.25
Leflunomide 2.04 (0.78–5.32) 0.14 0.9 (0.2 to 1.6) 0.010
Biologic therapy 0.51 (0.23–1.13) 0.098 −0.2 (−0.8 to 0.3) 0.35
Anti-TNF-α therapy 0.89 (0.36–2.23) 0.81 0.4 (−0.3 to 1.0) 0.23
Tocilizumab 0.16 (0.02–1.26) 0.081 −0.7 (−1.6 to 0.1) 0.085
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previous reports [9, 10]. In our study, DAS28, on a con-
tinuous basis, showed a trend toward being inversely re-
lated with CEC. Interestingly, patients with low and
moderate disease activity had statistically significant
lower CEC than those in remission. However, CEC was
not significantly different in patients with high disease
activity when compared with those in remission. A lack
of statistical power when comparing the high disease ac-
tivity group with patients in remission may be the reason
for this result because low and moderate disease activity
levels were linked to lower levels of CEC. Additionally,
when patients with moderate and high disease activity
were included in a single group and compared with
those in remission, the statistically significant association
was maintained. For this reason, we believe that the as-
sociation between disease activity and CEC found in our
study is robust enough to be considered real. In keeping
with our findings, Charles-Schoeman et al. [9] and
Ronda et al. [10] both described a relationship between
disease activity and CEC in their studies. In the former,
significant differences were noted between patients with
RA with low disease activity/clinical remission and pa-
tients with RA with high disease activity [9]. Significant
correlations were also found between CEC and RA dis-
ease activity and systemic inflammation as measured by
ESR [9]. In the latter study [10], a significant inverse cor-
relation was found between ABCG1-mediated CEC
values and DAS28 in patients with RA.
No other RA-related data different from the disease
activity findings were found to be associated with CEC
in our study. Only tocilizumab and NSAIDs showed a
relationship with CEC. The fact that tocilizumab
treatment was associated with increased levels of CEC is
in agreement with two recent reports that described a
beneficial effect of tocilizumab on CEC over time [22, 23].
However, the association of tocilizumab found in our
study should be interpreted with caution, given the small
number of patients included in our series. In our study,
NSAIDs were also associated with a protective effect for
CIMT and carotid plaque, as well as with higher levels of
CEC. This is in agreement with previous reports support-
ing the notion that in patients with inflammatory arthritis,
the anti-inflammatory effect of NSAIDs may compensate
for the potentially increased risk of cardiovascular disease
associated with these drugs [24, 25]. To the best of our
knowledge, the beneficial effects of NSAIDs over CEC
have not previously been described. However, we did not
find an association of prednisone intake with carotid sub-
clinical atherosclerosis. On one hand, we believe that this
is due to the fact that the risk of corticosteroids over car-
diovascular disease is dose-dependent and may be lower
or absent in patients receiving low-dose glucocorticoid
therapy [26]. On the other hand, we do not have an ex-
planation for the marginal protective effect of rheumatoid
factor over CIMT found in our series of white patients
with RA. It could be the result of a spurious correlation
that needs to be replicated in further studies. Nevertheless,
a recent study has shown an association between RA-
related autoantibodies with subclinical and clinical athero-
sclerosis in African American women but not in white
women or men [27].
The absence of any association between traditional
cardiovascular risk factors or lipid profile with CEC in
both patients and control subjects is in agreement with
previous reports. In this sense, traditional risk factors re-
portedly explain only 3% of the variance observed in
CEC [8]. Moreover, glucose tolerance status does not ap-
pear to impact CEC [28], and CEC cannot be explained
by HDL cholesterol or apolipoprotein A-I levels [29].
Similarly, we did not find any association of statins with
CEC in patients and control subjects. This finding sup-
ports the claim that statins most likely exert therapeutic
benefit by means of a mechanism that is different from
the promotion of cholesterol efflux [7]. Smoking has also
Table 3 Univariate relationship of characteristics of patients with rheumatoid arthritis with carotid intima-media thickness and
carotid plaques (Continued)
Rituximab 0.42 (0.05–3.80) 0.44 −1.1 (−2.4 to 0.1) 0.81
Abatacept 1.71 (0.11–27.8) 0.71 0.6 (−1.4 to 2.6) 0.55
Abbreviations: CRP C-reactive protein, LDL Low-density lipoprotein, NSAID Nonsteroidal anti-inflammatory drug; DMARD Disease-modifying antirheumatic drug, ESR
Erythrocyte sedimentation rate, DAS28 Disease Activity Score in 28 joints, HDL High-density lipoprotein, SDAI Simplified Disease Activity Index, CDAI Clinical Disease
Activity Index, TNF-α Tumor necrosis factor-α, ACPA Anticitrullinated protein antibody, CIMT Carotid intima-media thickness, ApoA Apolipoprotein A, ApoB Apolipo-
protein B. Significant 'p' values are higlighted in italics
Table 4 Cholesterol efflux capacity relationship with carotid intima-media thickness and carotid plaque
Carotid plaque CIMT (×10 mm)
Cholesterol efflux capacity OR (95% CI) p β Coefficient (95% CI) p
Unadjusted 0.95 (0.92–0.99) 0.023 0.01 (−0.02 to 0.03) 0.67
Adjusted 0.94 (0.89–0.98) 0.015 0.01 (−0.02 to 0.03) 0.54
Adjusted for age, sex, systolic blood pressure, diabetes, ESR, disease duration, DAS28 and tocilizumab use
CIMT Carotid intima-media thickness
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been found to be a significant inverse predictor of CEC
in previous studies [7]. However, we did not find this as-
sociation in our study. On one hand, we think it could
be due to our study design because we included only
current smokers. On the other hand, only 16% of the pa-
tients with RA included in our series were current
smokers at the time of the assessment. Nevertheless, we
feel that CEC impairment in RA may be predominantly
the result of an inflammation-related disturbance rather
the effect of traditional cardiovascular risk factors.
CEC was associated with carotid plaque in our study.
However, this was not the case for CIMT. We believe that
the relationship of CEC with CIMT is probably not linear;
thus, linear regression may have failed to detect this asso-
ciation. Nevertheless, carotid plaque is considered to be a
better predictor of cardiovascular disease than CIMT [30].
It is also known that whereas plaque reflects advanced
atherosclerosis and associates closely with dyslipidemia,
increased CIMT represents mostly high blood pressure-
mediated arterial medial hypertrophy and relates more
strongly to left ventricular hypertrophy and stroke [31].
For this reason, we think that the association with carotid
plaque and not with CIMT found in our study is consist-
ent with previous knowledge regarding the etiopathogen-
esis of atherosclerotic disease.
We acknowledge several limitations in our study. First,
carotid assessments were not available for healthy con-
trol subjects. Although CEC has been widely associated
with CIMT and cardiovascular events in the general
population, the availability of carotid assessments in
control subjects would have allowed us to study a differ-
ent effect or statistical interaction between these two
populations. Second, as previously mentioned, CEC
pathways are diverse, and some other molecules may be
implicated in CEC. Finally, although there are other
ways of assessing cholesterol efflux in vitro, most
research done in population-based cohorts has been
carried out using the same assay as the one described in
our study. This assay integrates the pathways known to
mediate cholesterol efflux from macrophages (i.e.,
ABCA1, ABCG1, SR-BI, and AD).
Conclusions
Our study, which includes the largest series of patients
with RA ever assessed for CEC, reveals for the first time,
to our knowledge, that CEC is related to subclinical ath-
erosclerosis in patients with RA. The fact that CEC is
also associated with disease activity reinforces the idea
that CEC may be a mediator between disease activity
and subclinical atherosclerosis. We emphasize the po-
tential role of checking CEC in patients with RA because
it may be a complementary approach to the assessment
of atherosclerotic disease in these patients. We feel that
our findings herald a new opportunity for research in
this area in which future investigations are warranted.
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